 CARLSBAD, Calif., Jan. 05, 2022 GLOBE NEWSWIRE -- Pardes Biosciences, Inc. NASDAQ: PRDS, a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases i.e. COVID-19, today announced that Uri A. Lopatin, M.D., Chief Executive Officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 7:30 a.m. PT 10:30 a.m. ET. The virtual conference will be held from January 10-13, 2022. 